Engen Bio Overview
EnGen Bio's lead program focuses on developing an effective, easy-to-manufacture, shelf-stable vaccine and therapy to confer long-term immunity to all Type A influenza strains, including all flu pandemics, all Type A seasonal flus, and all animal flus.
Our goal: with one or two shots, you could be protected from the worst seasonal influenza viruses, and all pandemic influenza strains for life. Or, if you have already been exposed or have come down with the flu, our therapy could offer you a treatment.
Our vaccine for humans and animals and our therapy for humans are based on our discovery that a small region of a particular flu protein has very strong constraints against mutation. When used to vaccinate test animals, this region of the protein appears to elicit a highly protective antibody response upon viral challenge.
Did I Invest In Engen Bio?
I’m still in the process of writing a full deal report and decide whether or not I will invest in Engen Bio. I review 100+ startups on 10+ platforms every month and send a detailed report every Saturday to subscribers of the Angel Notes newsletter (you can join through the form below). See you soon!